Article Text

Download PDFPDF

AB0949 The annual cost of patients with juvenile idiopathic arthritis
  1. B Serpen1,
  2. O Altug-Gucenmez1,
  3. C Acari1,
  4. MK Sozmen2,
  5. B Makay1,
  6. SE Unsal1
  1. 1Faculty of Medicine, Unit of Pediatric Rheumatology, Dokuz Eylul University
  2. 2Faculty of Medicine, Department of Public Health, Izmir Katip Celebi University, Izmir, Turkey


Background The management of juvenile idiopathic arthritis (JIA) includes various methods including such as medication, hospitalization, rehabilitation.

Objectives To determine how much juvenile idiopathic arthritis cost; the components of this cost; how new treatments, i.e. biologics, improve the disease course and hospital expenditures.

Methods This study was conducted in Dokuz Eylul University, Pediatric Rheumatology Unit between March 2015-March 2016. One-hundred six JIA patients who had a follow-up period of at least 1 year according to International Edmonton 2001 criteria were included. This retrospective cost study evaluated the data of these patients and calculated the direct cost for the follow-up period. Clinical data was collected from patient files that were in department's archive and cost data was gathered from Probel Hospital Information Management system. Patient data form covering sociodemographic and clinical information, patient drug form and annual medical cost form was filled out for each patient.

Results 58.5% (n=62) of patients was female and 41.5% (n=44) was male. The mean age was 12.0±4.3 years. 34.0% (n=36) of patients was oligoarticular type, 28.3% (n=30) was poliarticular type, 22.6% (n=24) was enthesitis related arthritis (ERA), 8,5% (n=9) was psoriatic type and 6.6% (n=7) was systemic type. The cost of medication counted for 88.3% (453244.94 TL) of total direct annual cost. Total direct medical cost was highest for ERA (n=7742.55±9891 TL). While the annual cost was calculated as 10451 TL per person for biologic using patients, for the patients using non-biologic treatments it was determined as 1472 TL per person. 1 TL=0.32 € 1 TL =0.35 $

Conclusions Medication is responsible for most of the total direct medical cost in patients with JIA. Our results showed concordance with previous studies on the subject. This situation could be attributed to biologic agents that are being used in treatment in recent years. More prospective studies on the effectiveness of cost of treatment, with greater amount of patient and more homogenous subgroups are needed.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.